UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
December 15, 2011 (December 15, 2011)
NEUROGESX, INC.
(Exact name of registrant as specified in its charter)
| | | | |
| DELAWARE | | 001-33438 | | 94-3307935 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
2215 Bridgepointe Parkway, Suite 200, San Mateo, California 94404
(Address of principal executive offices, including zip code)
650-358-3300
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On December 15, 2011, NeurogesX, Inc. (the “Company”), issued a press release entitled “NeurogesX Confirms FDA Advisory Committee to Review sNDA for Qutenza® (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN)”. A copy of the press release is filed as Exhibit 99.1 to this Form 8-K. The content of the press release is deemed to be filed for purposes of the Securities Exchanged Act of 1934, as amended.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
The following exhibits are filed as part of this Current Report on Form 8-K.
| | |
Exhibit No. | | Description |
| |
| 99.1 | | Press Release entitled “NeurogesX Confirms FDA Advisory Committee to Review sNDA for Qutenza® (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN)”. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | |
| NEUROGESX, INC. |
| |
| By: | | /s/ Stephen F. Ghiglieri |
| | Stephen F. Ghiglieri |
| | Executive Vice President, Chief Operating Officer and Chief Financial Officer |
Date: December 15, 2011
3
EXHIBIT LIST
| | |
Exhibit No. | | Description |
| |
| 99.1 | | Press Release entitled “NeurogesX Confirms FDA Advisory Committee to Review sNDA for Qutenza® (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN)”. |
4
